ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Our Product: Pegloprastide Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is designed to deliver a fluorescent marker specifically to cancer cells to enable surgeons to identify cancerous tissue in real-time and thus, avoid repeat surgeries and improve patient outcomes. Pegloprastide is the only fluorescence-based clinical cancer detection product that uses the ratio of two fluorophores within the same molecule (ratiometric imaging) to provide more accurate and actionable information during a procedure. Pegloprastide is currently an investigational product under development in human clinical trials. A recent Phase 2 registration study of the use of pegloprastide during breast cancer surgery met its primary endpoint of detecting cancer in margin specimens in real time (p < 0.001). Additional top-line data analysis found: Use of pegloprastide during surgery correctly identified cancer in up to 75% of patients who may have otherwise been candidates for a repeat (re-excision) surgery Overall accuracy of pegloprastide in detecting true positive or true negative patients was ~81% While the current typical re-excision rate among initial lumpectomies is estimated at 20-40%, the observed re-excision rate in this prospective study was ~6% In clinical studies, pegloprastide has been administered by intravenous (IV) injection between ~3-20 hours prior to surgery. In more than 150 patients dosed to date, no drug-related serious adverse events have been reported. Given the potential broad applicability of pegloprastide due to its MMP-driven mechanism of action, Avelas plans to explore the use of pegloprastide to improve outcomes in a variety of other non-breast cancer surgeries, such as ovarian, colorectal, head and neck, melanoma, and sarcoma. For more information on pegloprastide’s clinical experience, please visit our Clinical Trials page. HOME ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Copyright © Avelas Biosciences | Website by AshWebStudio

ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Pipeline Pegloprastide has the potential to become part of standard-of-care treatment for a variety of cancer surgeries HOME ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Copyright © Avelas Biosciences | Website by AshWebStudio